导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.90% | 1771/4345 |
| 近一周 | -1.79% | 2545/4962 |
| 近一月 | -9.02% | 4665/4922 |
| 近一季 | -20.89% | 4510/4747 |
| 近半年 | -1.62% | 1674/4477 |
| 近一年 | 6.73% | 1419/4016 |
| 近两年 | 123.17% | 363/2712 |
| 近三年 | 80.58% | 208/2054 |
| 成立以来 | 99.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.36% 2255/4961 |
36.93% 870/5312 |
- - |
- - |
| 2025 | 55.40% 326/4813 |
-3.28% 3034/3635 |
3.95% 902/4076 |
55.59% 179/4524 |
-0.65% 2578/4813 |
| 2024 | 20.77% 441/3463 |
-1.63% 1252/2808 |
-6.58% 1980/3014 |
31.01% 118/3129 |
0.31% 1232/3463 |
| 2023 | -22.06% 1917/2656 |
-0.59% 1806/2280 |
-7.70% 1892/2385 |
-9.96% 1915/2515 |
-5.66% 1446/2655 |
| 2022 | -28.08% 1530/2207 |
-19.56% 1474/1919 |
6.88% 582/2016 |
-18.66% 1730/2113 |
2.84% 821/2208 |
| 2021 | 15.54% 305/1822 |
-5.66% 945/1255 |
29.87% 46/1330 |
-6.58% 961/1466 |
0.94% 1039/1822 |
| 2020 | 77.97% 47/1250 |
4.27% 79/1028 |
32.17% 33/1067 |
8.25% 724/1164 |
19.30% 76/1184 |
| 2019 | 45.76% 145/1092 |
30.33% 255/754 |
-9.17% 636/804 |
7.89% 75/850 |
14.13% 25/918 |
| 2018 | -42.79% 617/834 |
- - |
- - |
- - |
-17.53% 651/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安创业板50ETF联接A VS. 长安沪深300非周期A(740101) |